Asbaghi O, Ghanbari N, Shekari M, et al
These benefits apply whether youre seeking to fine-tune or completely overhaul your figure
The American Association of Clinical Endocrinology (AACE) 2022 obesity guidelines, available at aace.com, explicitly list GLP-1 receptor agonists as second-line pharmacotherapy for patients with insulin resistance or metabolic obesity
The side effects are comparable Patients can expect similar side effects to that of injectable GLP-1: Nausea, headaches, fatigue, vomiting, diarrhea, and sometimes more serious gastrointestinal issues are only a few
Summary: Mounjaro (tirzepatide) reduces food noise by activating GIP and GLP-1 receptors in appetite-regulating brain regions, mimicking natural satiety hormones to decrease hunger, cravings, and persistent food-related thoughts
Circ Cardiovasc Genet 7 , 321331 (2014)